107 related articles for article (PubMed ID: 23363746)
1. [Proliferation-inhibiting and multidrug-resistant reversing effect of bortezomib on human HL-60 cells].
Shang J; Chen ZZ; Wu WB; Wei TN; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):911-6. PubMed ID: 23363746
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
Zheng B; Zhou R; Gong Y; Yang X; Shan Q
Int J Lab Hematol; 2012 Jun; 34(3):237-47. PubMed ID: 22145750
[TBL] [Abstract][Full Text] [Related]
3. [Effect of proteasome inhibitor bortezomib on proliferation, apoptosis and XIAP expression in K562 cells].
Shao M; Sun L; Cui XY; Han XF; Chen SM; Wang F; Zhang H; Ling Z
Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):182-6. PubMed ID: 21535957
[TBL] [Abstract][Full Text] [Related]
4. [In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
Cai YX; Meng FY; Sun QX; Fu YB; Li L
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):737-40. PubMed ID: 19176009
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of nucleophosmin by RNA interference reverses multidrug resistance in resistant leukemic HL-60 cells.
Lin M; Hu J; Liu T; Li J; Chen B; Chen X
Immunobiology; 2013 Sep; 218(9):1147-54. PubMed ID: 23669237
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib.
Li YC; Wang HH; Liao AJ; Fu BB; Zhang R; Li J; Yang Y; Liu ZG; Yang W
Eur Rev Med Pharmacol Sci; 2014; 18(10):1465-72. PubMed ID: 24899604
[TBL] [Abstract][Full Text] [Related]
7. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR.
Tang XQ; Bi H; Feng JQ; Cao JG
Acta Pharmacol Sin; 2005 Aug; 26(8):1009-16. PubMed ID: 16038636
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
9. [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
Zhou RQ; Gong YP; Zheng BH; Yang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):789-92. PubMed ID: 21302442
[TBL] [Abstract][Full Text] [Related]
10. [Reversing effects of emodin on multidrug resistance in resistant HL-60/ADR cells].
Chen YY; Li J; Hu JD; Zheng J; Zheng ZH; Zhu LF; Chen XJ; Lin ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1413-22. PubMed ID: 24370022
[TBL] [Abstract][Full Text] [Related]
11. [Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
Jiang XJ; Meng FY; Zhou HS; Wang Q; Wu FQ; Huang KK; Huang M; Wang ZX; Chen WW
Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):537-42. PubMed ID: 22338177
[TBL] [Abstract][Full Text] [Related]
12. [Effect of rapamycin on proliferation of acute myeloid leukemia cell lines HL-60 and HL-60/VCR].
Liang R; Xiong H; Wang Z; Chen XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1464-8. PubMed ID: 21176352
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of bortezomib and daunorubicin on multiple myeloma cell KM3 in vitro.
Ouyang GF; Lin MF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1468-71. PubMed ID: 20030928
[TBL] [Abstract][Full Text] [Related]
14. [The influence of bortezomib on HL-60 cell function induced by all-trans retinoic acid plus bufalin and its mechanism].
Qu XJ; Ma YJ; Liu YP
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):828-31. PubMed ID: 19176038
[TBL] [Abstract][Full Text] [Related]
15. [Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].
Fu YB; Sun QX; Meng FY; Xie J; Zhou GB
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2413-6. PubMed ID: 17156654
[TBL] [Abstract][Full Text] [Related]
16. [Effect of bortezomib on MAPK signaling pathway of K562/DNR cells].
Liao AJ; Fu BB; Wang HH; Li YC; Yao K; Zhang R; Yang W; Liu ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1460-3. PubMed ID: 21176351
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Minderman H; Zhou Y; O'Loughlin KL; Baer MR
Cancer Chemother Pharmacol; 2007 Jul; 60(2):245-55. PubMed ID: 17096161
[TBL] [Abstract][Full Text] [Related]
18. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
19. [Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM].
Cai X; Chen FY; Han JY; Gu CH; Zhong H; Ouyang RR
Ai Zheng; 2004 Dec; 23(12):1611-5. PubMed ID: 15601547
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
